When multiple myeloma relapses
RESPOND with deeper response with Kyprolis®-based regimen (KRd)
KRd complete response
In the ASPIRE trial, KRd showed more than a 3 times higher rate of CR vs Rd.1
Adapted from Stewart et al.1
A KRd regimen results in higher QoL vs Rd
*Descriptive P value.
Please read the SmPC for full comprehensive safety information
- Stewart AK et al. N Engl J Med 2015;372:142–152.